Biotech firm gets Chinese patent on plant substance cocktail for diabetes, obesity and fatty liver prevention

Chinese authorities have issued a patent to French biotech firm Valbiotis which will use plant substances to prevent a series of cardiometabolic illnesses such as diabetes and obesity.

Photo: Malina Petr/AP/Ritzau Scanpix

French biotech company Valbiotis has ensured patent protection in China for the company's active ingredient TOTUM-63 which has shown effects on a series of risk factors for type 2 diabetes, for example, according to a press statement from the firm.

Since its foundation in 2014, Valbiotis has worked with nutrition healthcare and the prevention of type 2 diabetes, obesity cardiovascular illnesses and nonalcoholic fatty liver disease (NASH).

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs